Akeso Biopharma (Cayman) Limited (Akeso) submitted the latest monthly report on securities changes to The Hong Kong Exchanges and Clearing Limited on November 4, 2024, reporting the shareholding changes as of October 31, 2024. The report indicates that Akeso did not have any changes in its statutory/registered share capital for that month, with a remaining balance of 5,000,000,000 shares, each with a par value of $0.00001, totaling $50,000 of statutory/registered share capital. However, the company's issued shares (excluding treasury shares) increased from 865,857,176 shares last month to 897,557,176 shares, an increase of 31,700,000 shares. This increase in shares was based on a placement agreement dated October 11, 2024, and the issuance of new shares was completed under a general authorization placement on October 21, 2024. In terms of share options, the...Show More

Akeso Biopharma (Cayman) Limited (Akeso) submitted the latest monthly report on securities changes to The Hong Kong Exchanges and Clearing Limited on November 4, 2024, reporting the shareholding changes as of October 31, 2024. The report indicates that Akeso did not have any changes in its statutory/registered share capital for that month, with a remaining balance of 5,000,000,000 shares, each with a par value of $0.00001, totaling $50,000 of statutory/registered share capital. However, the company's issued shares (excluding treasury shares) increased from 865,857,176 shares last month to 897,557,176 shares, an increase of 31,700,000 shares. This increase in shares was based on a placement agreement dated October 11, 2024, and the issuance of new shares was completed under a general authorization placement on October 21, 2024. In terms of share options, the company, under the Share Options Scheme adopted on June 28, 2022, and amended on June 30, 2024, had 394,000 share options outstanding at the end of this month, with no change during the month, and a potential issuance or transfer from treasury of 91,000 shares. Akeso confirms that all securities issuances or sales of treasury shares have been formally authorized by the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.